- Home
- NETD vs EBS Comparison
NETD vs EBS Comparison
Compare NETD & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- EBS
- Stock Information
- Founded
- NETD 2023
- EBS 1998
- Country
- NETD United States
- EBS United States
- Employees
- NETD N/A
- EBS N/A
- Industry
- NETD
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- EBS Health Care
- Exchange
- NETD Nasdaq
- EBS Nasdaq
- Market Cap
- NETD 422.4M
- EBS 359.3M
- IPO Year
- NETD 2023
- EBS 2006
- Fundamental
- Price
- NETD $11.17
- EBS $7.16
- Analyst Decision
- NETD
- EBS Strong Buy
- Analyst Count
- NETD 0
- EBS 3
- Target Price
- NETD N/A
- EBS $14.33
- AVG Volume (30 Days)
- NETD 243.1K
- EBS 1.4M
- Earning Date
- NETD 01-01-0001
- EBS 08-06-2025
- Dividend Yield
- NETD N/A
- EBS N/A
- EPS Growth
- NETD N/A
- EBS N/A
- EPS
- NETD 0.34
- EBS N/A
- Revenue
- NETD N/A
- EBS $965,400,000.00
- Revenue This Year
- NETD N/A
- EBS N/A
- Revenue Next Year
- NETD N/A
- EBS $16.15
- P/E Ratio
- NETD $32.80
- EBS N/A
- Revenue Growth
- NETD N/A
- EBS N/A
- 52 Week Low
- NETD $10.58
- EBS $4.02
- 52 Week High
- NETD $11.47
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- NETD 54.61
- EBS 53.48
- Support Level
- NETD $10.96
- EBS $6.89
- Resistance Level
- NETD $11.24
- EBS $7.83
- Average True Range (ATR)
- NETD 0.12
- EBS 0.37
- MACD
- NETD 0.00
- EBS -0.00
- Stochastic Oscillator
- NETD 41.18
- EBS 42.80
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.